ArticleBreast cancer research and treatment2020
Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.
Open access · greenAbstract read
In one paragraph
Article in Breast cancer research and treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 46 citations in OpenAlex.
- Review of ctDNA in breast cancer - present utility and future perspectives.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026Review
- Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer.Frontiers in oncology · 2026Review
- Precision Oncology Framework Using Circulating Tumor Cells.International journal of molecular sciences · 2025Review
- Lessons (to be) learned from liquid biopsies: assessment of circulating cells and cell-free DNA in cancer and pregnancy-acquired microchimerism.Seminars in immunopathology · 2025Review
- Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review.Frontiers in oncology · 2025Review
- Concordance of HER2 status between primary tumor and circulating tumor cells in breast cancer.Discover oncology · 2024Article
- Personalized treatment approach for HER2-positive metastatic breast cancer.Medical oncology (Northwood, London, England) · 2024Review
- Article
- Identification of novel membrane markers in circulating tumor cells of mesenchymal state in breast cancer.Biochemistry and biophysics reports · 2024Article
- Comparing the HER2 Status of the Primary Tumor to That of Disseminated Tumor Cells in Early Breast Cancer.International journal of molecular sciences · 2024Article
- Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy.Frontiers in oncology · 2024Review
- Circulating tumor cells in gastric cancer: developments and clinical applications.Clinical and experimental medicine · 2023Review
- Review
- Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer.International journal of molecular sciences · 2023Review
- Utilization of Circulating Tumor Cells in the Management of Solid Tumors.Journal of personalized medicine · 2023Review
- Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting.Cancers · 2023Review
- Article
- Detection of circulating tumor cells: opportunities and challenges.Biomarker research · 2022Review
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 4 institutions in 1 country.
Chun WangDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Zhaomei MuDivision of Hematology and Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Zhong YeDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Zhenchao ZhangDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Maysa M Abu-KhalafDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Daniel P SilverDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Juan P PalazzoDepartment of Pathology, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Geetha JagannathanDepartment of Pathology, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Frederick M FellinDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Saveri BhattacharyaDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Rebecca J JaslowDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Theodore N TsangarisDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Adam BergerDepartment of Surgery, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Manish NeupaneDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Terrence P CesconDepartment of Hematology Oncology, Reading Hospital, West Reading, PA, 19611, USA.
AnaMaria LopezDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Kaelan YaoDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Weelic ChongDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Brian LuDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Ronald E MyersDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Lifang HouDepartment of Preventive Medicine, Northwestern University, Chicago, IL, 60611, USA.
Qiang WeiDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, 37235, USA.
Bingshan LiDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, 37235, USA.
Massimo CristofanilliDivision of Hematology and Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA. massimo.cristofanilli@nm.org.
Hushan YangDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA. hushan.yang@jefferson.edu.ORCID http://orcid.org/0000-0001-9920-1731
Thomas Jefferson University · USNorthwestern University · USVanderbilt University · USReading Hospital · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MX-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Andrew Chapman · 1995 to 2026
$94.8MNorthwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8MA population-based approach to single CTC analysis in metastatic breast cancer outcomeR01CA207468 · NCI · THOMAS JEFFERSON UNIVERSITY · PI YANG, HUSHAN · 2017 to 2022
$2.7MDivision of Cancer Prevention, National Cancer Institute R01CA207468NCATS NIH HHS UL1 TR001422NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA056036NCI NIH HHS R01 CA207468
Abstract
purposeDiscordance between HER2 expression in tumor tissue (tHER2) and HER2 status on circulating tumor cells (cHER2) has been reported. It remains largely underexplored whether patients with tHER2
methodscHER2 status was determined in 105 advanced-stage patients with tHER2
resultsCompared to the patients with low-risk cHER2 (cHER2
conclusionIn advanced-stage breast cancer patients with tHER2
Indexed as
Biomarkers, TumorBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoplasm StagingNeoplastic Cells, CirculatingSurvival RateBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesBreast cancerCirculating tumor cell (CTC)Human epidermal growth factor receptor 2 (HER2)Progression-free survival (PFS)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.